Ibrutinib is a cancer medicine sold under the brand name Imbruvica. It is used for the treatment of patients suffering from mantle cell lymphoma (MCL).
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Waldenström’s macroglobulinemia (WM)
Marginal zone lymphoma (MZL)
Chronic graft-versus-host disease (GVHD)
This medication comes in the form of capsules and has a fixed strength of 140 mg. This is a prescription-based medicine, as it may show some side effects like joint pain
Recent Comments